Merck (MRK) Deferred Taxes (2009 - 2026)

Merck has disclosed Deferred Taxes across 18 years of filings, most recently posting -$315.0 million for Q1 2026.

• In Q1 2026, Deferred Taxes fell 69.35% year-over-year to -$315.0 million; the TTM figure through Mar 2026 stood at -$1.8 billion (down 30.06% YoY), while the FY2025 annual figure was -$1.7 billion, down 33.79% from the prior year.
• Deferred Taxes improved to -$315.0 million in Q1 2026, from -$825.0 million in the prior quarter.
• Over the last five years, Deferred Taxes for MRK reached as high as -$51.0 million in Q1 2024 and fell as low as -$931.0 million in Q4 2023.
• The 5-year median for Deferred Taxes is -$336.0 million (2023), against an average of -$394.2 million.
• Annual changes were most pronounced in 2022 — Deferred Taxes tumbled 66000.0% — and 2024, when it soared 81.59%.
• A 5-year view of Deferred Taxes shows it stood at -$307.0 million in 2022, then plunged by 203.26% to -$931.0 million in 2023, then soared by 33.83% to -$616.0 million in 2024, then slumped by 33.93% to -$825.0 million in 2025, then soared by 61.82% to -$315.0 million in 2026.
• According to Business Quant data, Deferred Taxes over the past three periods registered -$315.0 million, -$825.0 million, and -$212.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.